Novartis: Seizures trials
The registry lists 11 Seizures studies with Novartis as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 2Phase 2 2Phase 3 6Phase 4 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresCompletedNCT01713946Phase 3Results posted
- Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset SeizuresCompletedNCT00975715Phase 2/3Results posted
- Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3Results posted
- Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentActive, not recruitingNCT02962414Phase 3
- To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting ConditionsCompletedNCT00946751Phase 1
- Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy SurgeryCompletedNCT00887861Phase 2
- Bioequivalence Study of Divalproex Sodium 125 MG Delayed Release Tablets Under Fasting ConditionsCompletedNCT00864006Phase 1
- Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial SeizuresCompletedNCT00275925Phase 4
- Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial SeizuresCompletedNCT00275912Phase 4
- Pediatric Epilepsy StudyCompletedNCT00050947Phase 3
- Pediatric Epilepsy StudyCompletedNCT00050934Phase 3